Jarlego, Cliff S.
HRN: 23 23 12 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/06/2023
MUPIROCIN 2%, 15G (TUBE)
07/06/2023
07/13/2023
TOPICAL
2%
TID
Bed Sore
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes